journal
MENU ▼
Read by QxMD icon Read
search

Current Oncology

journal
https://www.readbyqxmd.com/read/28050154/treatment-and-outcomes-for-primary-cutaneous-extramedullary-plasmacytoma-a-case-series
#1
D S Tsang, L W Le, V Kukreti, A Sun
BACKGROUND: Primary cutaneous plasmacytoma (pcp) is a rare disease, with few studies to guide therapy. Our primary study objective was to define treatments used for pcp; a secondary objective was to describe outcomes of patients, including disease recurrence and death. METHODS: An institutional cancer registry was used to identify cases for retrospective chart review. In a systematic review, treatments for, and outcomes of, all known cases of pcp were described...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28050153/cancer-referral-and-treatment-activity-2010-2015-a-population-based-study-from-vancouver-island
#2
P Savage, C Holloway, G Lindsay, K Shubrook, C Jones, M Fung, K Schaff, H Anderson, K Nystedt, J Rauw
INTRODUCTION: The years since 2005 have seen major changes in cancer treatment and significant increases in the number of anticancer drugs available. However, there are relatively few published data to reflect how those changes are affecting the activity and workload of oncology services. To explore the effects of those changes, we reviewed the population-based cancer treatment activity on Vancouver Island for the period 2010-2015. METHODS: Information about new patient referrals, radiation courses, new chemotherapy cycles commenced, total intravenous (IV) chemotherapy treatment visits, and pharmacy activity for oral anticancer drug prescriptions was obtained from BC Cancer Agency databases...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28050152/recommendations-on-breast-cancer-screening-and-prevention-in-the-context-of-implementing-risk-stratification-impending-changes-to-current-policies
#3
J Gagnon, E Lévesque, F Borduas, J Chiquette, C Diorio, N Duchesne, M Dumais, L Eloy, W Foulkes, N Gervais, L Lalonde, B L'Espérance, S Meterissian, L Provencher, J Richard, C Savard, I Trop, N Wong, B M Knoppers, J Simard
In recent years, risk stratification has sparked interest as an innovative approach to disease screening and prevention. The approach effectively personalizes individual risk, opening the way to screening and prevention interventions that are adapted to subpopulations. The international perspective project, which is developing risk stratification for breast cancer, aims to support the integration of its screening approach into clinical practice through comprehensive tool-building. Policies and guidelines for risk stratification-unlike those for population screening programs, which are currently well regulated-are still under development...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28050151/eastern-canadian-gastrointestinal-cancer-consensus-conference-2016
#4
D Bossé, T Ng, C Ahmad, A Alfakeeh, I Alruzug, J Biagi, J Brierley, P Chaudhury, S Cleary, B Colwell, C Cripps, L A Dawson, M Dorreen, E Ferland, P Galiatsatos, S Girard, S Gray, F Halwani, N Kopek, A Mahmud, G Martel, L Robillard, B Samson, M Seal, J Siddiqui, L Sideris, S Snow, M Thirwell, M Vickers, R Goodwin, R Goel, T Hsu, E Tsvetkova, B Ward, T Asmis
The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016 was held in Montreal, Quebec, 5-7 February. Experts in radiation oncology, medical oncology, surgical oncology, and infectious diseases involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics: ■ Follow-up and survivorship of patients with resected colorectal cancer■ Indications for liver metastasectomy■ Treatment of oligometastases by stereotactic body radiation therapy■ Treatment of borderline resectable and unresectable pancreatic cancer■ Transarterial chemoembolization in hepatocellular carcinoma■ Infectious complications of antineoplastic agents...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28050150/risk-stratification-treatment-selection-and-transplant-eligibility-in-multiple-myeloma-a-qualitative-study-of-the-perspectives-and-self-reported-practices-of-oncologists
#5
T W LeBlanc, A Howson, W Turell, P Sheldon, S C Locke, S A Tuchman, C Gasparetto, S Kaura, Z M Khan, A P Abernethy
BACKGROUND: Since the early 2000s, treatment options for multiple myeloma have rapidly expanded, adding significant complexity to the management of this disease. To our knowledge, no systematic qualitative research on clinical decision-making in multiple myeloma has been published. We sought to characterize how physicians view and implement guidelines and incorporate novel approaches into patient care. METHODS: We designed a semi-structured qualitative interview guide informed by literature review and an expert advisory panel...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28050149/treatment-patterns-and-survival-in-patients-with-alk-positive-non-small-cell-lung-cancer-a-canadian-retrospective-study
#6
S Kayaniyil, M Hurry, J Wilson, P Wheatley-Price, B Melosky, J Rothenstein, V Cohen, C Koch, J Zhang, K Osenenko, G Liu
BACKGROUND: Crizotinib was the first agent approved for the treatment of anaplastic lymphoma kinase (ALK)-positive (+) non-small-cell lung cancer (nsclc), followed by ceritinib. However, patients eventually progress or develop resistance to crizotinib. With limited real-world data available, the objective of the present work was to evaluate treatment patterns and survival after crizotinib in patients with locally advanced or metastatic ALK+ nsclc in Canada. METHODS: In this retrospective study at 6 oncology centres across Canada, medical records of patients with locally advanced or metastatic ALK+ nsclc were reviewed...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28050148/a-retrospective-analysis-of-the-role-of-proton-pump-inhibitors-in-colorectal-cancer-disease-survival
#7
C Graham, C Orr, C S Bricks, W M Hopman, N Hammad, R Ramjeesingh
BACKGROUND: Proton pump inhibitors (ppis) are a commonly used medication. A limited number of studies have identified a weak-to-moderate association between ppi use and colorectal cancer (crc) risk, but none to date have identified an effect of ppi use on crc survival. We therefore postulated that an association between ppi use and crc survival might potentially exist. METHODS: We performed a retrospective chart review of 1304 crc patients diagnosed from January 2005 to December 2011 and treated at the Cancer Centre of Southeastern Ontario...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28050147/sensor-controlled-scalp-cooling-to-prevent-chemotherapy-induced-alopecia-in-female-cancer-patients
#8
M K Fehr, J Welter, W Sell, R Jung, R Felberbaum
BACKGROUND: Scalp cooling has been used since the 1970s to prevent chemotherapy-induced alopecia, one of the most common and psychologically troubling side effects of chemotherapy. Currently available scalp cooling systems demonstrate varying results in terms of effectiveness and tolerability. METHODS: For the present prospective study, 55 women receiving neoadjuvant, adjuvant, or palliative chemotherapy were enrolled. The aim was to assess the effectiveness of a sensor-controlled scalp cooling system (DigniCap: Sysmex Europe GmbH, Norderstedt, Germany) to prevent chemotherapy-induced alopecia in breast or gynecologic cancer patients receiving 1 of 7 regimens...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28050146/personalized-oncogenomics-in-the-management-of-gastrointestinal-carcinomas-early-experiences-from-a-pilot-study
#9
B S Sheffield, B Tessier-Cloutier, H Li-Chang, Y Shen, E Pleasance, K Kasaian, Y Li, S J M Jones, H J Lim, D J Renouf, D G Huntsman, S Yip, J Laskin, M Marra, D F Schaeffer
BACKGROUND: Gastrointestinal carcinomas are genomically complex cancers that are lethal in the metastatic setting. Whole-genome and transcriptome sequencing allow for the simultaneous characterization of multiple oncogenic pathways. METHODS: We report 3 cases of metastatic gastrointestinal carcinoma in patients enrolled in the Personalized Onco-Genomics program at the BC Cancer Agency. Real-time genomic profiling was combined with clinical expertise to diagnose a carcinoma of unknown primary, to explore treatment response to bevacizumab in a colorectal cancer, and to characterize an appendiceal adenocarcinoma...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28050145/burden-of-illness-for-metastatic-melanoma-in-canada-2011-2013
#10
D S Ernst, T Petrella, A M Joshua, A Hamou, M Thabane, S Vantyghem, F Gwadry-Sridhar
BACKGROUND: Detailed epidemiology for patients with advanced metastatic melanoma in Canada is not well characterized. We conducted an analysis of patients with this disease in the province of Ontario, with the aim being to study the presentation, disease characteristics and course, and treatment patterns for malignant melanoma. METHODS: In this Canadian observational prospective and retrospective study of patients with malignant melanoma, we used data collected in the Canadian Melanoma Research Network (cmrn) Patient Registry...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28050144/effect-of-chemotherapy-on-health-related-quality-of-life-among-early-stage-ovarian-cancer-survivors-a-study-from-the-population-based-profiles-registry
#11
C S Bhugwandass, J M A Pijnenborg, B Pijlman, N P M Ezendam
BACKGROUND: There is wide variation in the application of adjuvant chemotherapy in early-stage epithelial ovarian cancer. Our aim was to assess differences in health-related quality of life (hrqol) between patients with early-stage ovarian cancer who did or did not receive chemotherapy as adjuvant treatment. METHODS: All patients diagnosed with early-stage ovarian cancer between 2000 and 2010 within the population-based Eindhoven Cancer Registry (n = 191) were enrolled in this study...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28050143/socioeconomic-status-and-lifestyle-behaviours-in-cancer-survivors-smoking-and-physical-activity
#12
H Naik, X Qiu, M C Brown, L Eng, D Pringle, M Mahler, H Hon, K Tiessen, H Thai, V Ho, C Gonos, R Charow, V Pat, M Irwin, L Herzog, A Ho, W Xu, J M Jones, D Howell, G Liu
PURPOSE: Smoking cessation and increased physical activity (pa) have been linked to better outcomes in cancer survivors. We assessed whether socioeconomic factors influence changes in those behaviours after a cancer diagnosis. METHODS: As part of a cross-sectional study, a diverse group of cancer survivors at the Princess Margaret Cancer Centre (Toronto, ON), completed a questionnaire about past and current lifestyle behaviours and perceptions about the importance of those behaviours with respect to their health...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28050142/annual-surveillance-mammography-after-early-stage-breast-cancer-and-breast-cancer-mortality
#13
L F Paszat, R Sutradhar, S Gu, E Rakovitch
BACKGROUND: After treatment for early-stage breast cancer (bca), annual surveillance mammography (asm) is recommended based on the assumption that early detection of an invasive ipsilateral breast tumour recurrence or subsequent invasive contralateral primary bca reduces bca mortality. METHODS: We studied women with unilateral early-stage bca treated by breast-conserving surgery from 1994 to 1997 who subsequently developed an ipsilateral recurrence or contralateral primary more than 24 months after initial diagnosis, without prior regional or distant metastases...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28050141/stakeholder-views-on-participant-selection-for-first-in-human-trials-in-cancer-nanomedicine
#14
P Satalkar, B S Elger, D M Shaw
BACKGROUND: Participant selection for first-in-human (fih) trials involves complex decisions. The trial design makes it unlikely that participants will receive clinically relevant therapeutic benefit, but they are likely to experience risks of various magnitudes and types. The aim of the present paper was to describe and discuss the views of investigators and ethics committee members about the choice of trial participants for fih trials in cancer nanomedicine. METHODS: We drew insights from an exploratory qualitative study involving thematic analysis of 46 in-depth interviews with key stakeholders in Europe and North America involved in fih nanomedicine trials...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28050140/cancer-care-in-south-india-perspectives-from-visiting-canadian-oncologists
#15
S Karim, J C Del Paggio, S R Berry, C M Booth
No abstract text is available yet for this article.
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28050139/report-from-the-17th-annual-western-canadian-gastrointestinal-cancer-consensus-conference-edmonton-alberta-11-12-september-2015
#16
K E Mulder, S Ahmed, J D Davies, C M Doll, S Dowden, S Gill, V Gordon, P Hebbard, H Lim, A McFadden, J P McGhie, J Park, R Wong
The 17th annual Western Canadian Gastrointestinal Cancer Consensus Conference (wcgccc) was held in Edmonton, Alberta, 11-12 September 2015. The wcgccc is an interactive multidisciplinary conference attended by health care professionals from across Western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba) who are involved in the care of patients with gastrointestinal cancer. Surgical, medical, and radiation oncologists; pathologists; radiologists; and allied health care professionals participated in presentation and discussion sessions for the purposes of developing the recommendations presented here...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28050138/adjuvant-systemic-chemotherapy-for-stages-ii-and-iii-colon-cancer-after-complete-resection-a-clinical-practice-guideline
#17
B M Meyers, R Cosby, F Quereshy, D Jonker
BACKGROUND: Updated practice guidelines on adjuvant chemotherapy for completely resected colon cancer are lacking. In 2008, Cancer Care Ontario's Program in Evidence-Based Care developed a guideline on adjuvant therapy for stages ii and iii colon cancer. With newer regimens being assessed in this patient population and older agents being either abandoned because of non-effectiveness or replaced by agents that are more efficacious, a full update of the original guideline was undertaken...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28050137/emerging-therapies-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma
#18
REVIEW
D MacDonald, A Prica, S Assouline, A Christofides, T Lawrence, L H Sehn
With no treatment standard having been established for relapsed and refractory follicular lymphoma, a number of therapeutic approaches are used in Canada. In patients who relapse early or who eventually become resistant to subsequent treatment, prognosis is poor, and new approaches are needed. A number of novel therapies are being examined in this setting, including monoclonal antibodies, immunoconjugates, immunomodulatory agents, and signal transduction inhibitors. With the body of evidence for those emerging therapies accumulating and the standard upfront treatment changing from rituximab and chop (cyclophosphamide-doxorubicin-vincristine-prednisone) or rituximab and cvp (cyclophosphamide-vincristine-prednisone) to bendamustine and rituximab, treatment decisions in the relapsed and refractory setting have become more complex...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28050136/a-user-s-guide-to-cannabinoid-therapies-in-oncology
#19
REVIEW
V Maida, P J Daeninck
"Cannabinoid" is the collective term for a group of chemical compounds that either are derived from the Cannabis plant, are synthetic analogues, or occur endogenously. Although cannabinoids interact mostly at the level of the currently recognized cannabinoid receptors, they might have cross reactivity, such as at opioid receptors. Patients with malignant disease represent a cohort within health care that have some of the greatest unmet needs despite the availability of a plethora of guideline-driven disease-modulating treatments and pain and symptom management options...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28050135/the-risk-of-colorectal-cancer-is-not-increased-after-a-diagnosis-of-urothelial-cancer-a-population-based-study
#20
C H Harlos, H Singh, Z Nugent, A Demers, S M Mahmud, P M Czaykowski
BACKGROUND: The data about whether patients with a prior urothelial cancer (uca) are at increased risk of colorectal cancer (crc) are conflicting. We used a competing risks analysis to determine the risk of crc after uca. METHODS: Historical cohorts were assembled by record linkage of Manitoba Cancer Registry and Manitoba Health databases. The incidence of crc for individuals with uca as their first cancer between 1987 and 2009 was compared with the incidence for randomly selected age-and sex-matched individuals without a cancer diagnosis at the index date (uca diagnosis date)...
December 2016: Current Oncology
journal
journal
32168
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"